Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapy

Institutions

Publication Details

Journal
Haematologica
Published
2025-11-27
DOI
https://doi.org/10.3324/haematol.2025.287578
Primary Topic
Histiocytic Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapy

Haematologica
Histiocytic Disorders and Treatments
article

Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapy

article en

Abstract

No abstract available for this paper.
Haematologica
Beijing Children’s Hospital (CN)
Openalex Percentile: Top 54%
Histiocytic Disorders and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cell-free BRAF-V600E levels predict progression-free survival in children with Langerhans cell histiocytosis treated with dabrafenib and maintenance chemotherapy · Haematologica (2025) | TGRS Research Map | TGRS